Quick Answer
Sarepta Therapeutics, Inc. reported Total Revenue of $2.20 billion for the year ending 2025.
- Sarepta Therapeutics, Inc. showed an increase of +17.9% in Total Revenue from 2025 to 2025.
- This data is from Sarepta Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2016 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2018: $84.42 million | Q4 2018: $84.42 million | Q1 2019: $87.01 million | Q1 2019: $87.01 million | Q2 2019: $94.67 million | Q2 2019: $94.67 million | Q3 2019: $99.04 million | Q3 2019: $99.04 million | Q4 2019: $100.11 million | Q4 2019: $100.11 million | Q1 2020: $113.67 million | Q1 2020: $100.45 million | Q2 2020: $137.36 million | Q2 2020: $111.34 million | Q3 2020: $143.92 million | Q3 2020: $121.43 million | Q4 2020: $145.14 million | Q4 2020: $122.64 million | Q1 2021: $146.93 million | Q1 2021: $124.93 million | Q2 2021: $164.09 million | Q2 2021: $141.84 million | Q3 2021: $166.91 million | Q3 2021: $189.41 million | Q1 2022: $210.83 million | Q1 2022: $188.83 million | Q2 2022: $211.24 million | Q2 2022: $233.49 million | Q3 2022: $207.77 million | Q3 2022: $230.27 million | Q1 2023: $253.50 million | Q1 2023: $231.50 million | Q2 2023: $238.99 million | Q2 2023: $261.24 million | Q3 2023: $309.32 million | Q3 2023: $331.82 million | Q1 2024: $413.46 million | Q1 2024: $359.48 million | Q2 2024: $360.55 million | Q2 2024: $362.93 million | Q3 2024: $467.17 million | Q3 2024: $429.77 million | Q4 2024: $658.41 million | Q1 2025: $611.52 million | Q1 2025: $744.86 million | Q2 2025: $513.12 million | Q2 2025: $611.09 million | Q3 2025: $370.04 million | Q3 2025: $399.36 million | Q4 2025: $442.93 million.
- Over the full 19 years of available data (2016 to 2025), Sarepta Therapeutics, Inc.'s Total Revenue has grown by 40,450.4%.
- Historical annual values: Fiscal year 2025: $2.20 billion | Fiscal year 2025: $1.86 billion | Fiscal year 2024: $1.90 billion | Fiscal year 2024: $1.79 billion | Fiscal year 2023: $1.24 billion | Fiscal year 2023: $1.14 billion | Fiscal year 2022: $933.01 million | Fiscal year 2022: $843.77 million | Fiscal year 2021: $701.89 million | Fiscal year 2021: $612.40 million | Fiscal year 2020: $455.87 million | Fiscal year 2020: $540.10 million | Fiscal year 2019: $380.83 million | Fiscal year 2019: $380.83 million | Fiscal year 2018: $301.03 million | Fiscal year 2018: $301.03 million | Fiscal year 2017: $154.58 million | Fiscal year 2017: $154.58 million | Fiscal year 2016: $5.42 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: